Author

Kenneth Lundstrom

PanTherapeutics - Cited by 8,667 - Gene therapy - Cancer - Viral vectors - nutrigenomics

Biography

Dr.Kenneth Lundstrom has a broad expertise in gene expression,viral vectors andgene therapy. He received his Ph.D. in molecular genetics from the University of Helsinki, Finland and conducted post-doctoral research at Cetus Corporation in California. Dr. Lundstrom was appointed Senior Scientist at Orion Pharmaceuticals and was involved in studies on Catechol-o-methyltransferases. 
Title
Cited by
Year
Autoimmunity roots of the thrombotic events after COVID-19 vaccination
F Elrashdy, MM Tambuwala, SS Hassan, P Adadi, M Seyran, ...Autoimmunity reviews 20 (11), 102941, 2021202
35
2021
MSH3 homology and potential recombination link to SARS-CoV-2 furin cleavage site
BK Ambati, A Varshney, K Lundstrom, G Palú, BD Uhal, VN Uversky, ...Frontiers in Virology 2, 10, 2022202
19
2022
The importance of accessory protein variants in the pathogenicity of SARS-CoV-2
SS Hassan, PP Choudhury, GW Dayhoff II, AAA Aljabali, BD Uhal, ...Archives of biochemistry and biophysics 717, 109124, 2022202
16
2022
Emergence of unique SARS-CoV-2 ORF10 variants and their impact on protein structure and function
SS Hassan, K Lundstrom, Á Serrano-Aroca, P Adadi, AAA Aljabali, ...International Journal of Biological Macromolecules 194, 8-143, 2022202
12
2022
Implications derived from S-protein variants of SARS-CoV-2 from six continents
SS Hassan, K Lundstrom, D Barh, RJS Silva, BS Andrade, V Azevedo, ...International Journal of Biological Macromolecules 191, 934-955, 2021202
11
2021
Self-replicating vehicles based on negative strand RNA viruses
K LundstromCancer Gene Therapy 30 (6), 771-74, 2023202
8
2023
Mammalian expression systems and vaccination
MW Carroll, GWG Wilkinson, K LundstromGenetically engineered viruses, 10-15, 2023202
7
2023
An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2
SS Hassan, V Kodakandla, EM Redwan, K Lundstrom, PP Choudhury, ...PeerJ 10, e13136, 2022202
7
2022
Alphaviruses in Cancer Therapy
K LundstromFrontiers in Molecular Biosciences 9, 84781, 2022202
6
2022
Associations and disease–disease interactions of COVID-19 with congenital and genetic disorders: a comprehensive review
A Hromić-Jahjefendić, D Barh, CH Ramalho Pinto, ...Viruses 14 (), 910, 2022202
5
2022
Can COVID-19 Vaccines Induce Premature Non-Communicable Diseases: Where Are We Heading to?
A Hromić-Jahjefendić, D Barh, V Uversky, AA Aljabali, MM Tambuwala, ...Vaccines 11 (2), 208, 2023202
5
2023
Alphaviruses in immunotherapy and anticancer therapy
K LundstromBiomedicines 10 (9), 2263, 2022202
4
2022
Viral Vectors in Gene Therapy: Where Do We Stand in 2023?
K LundstromViruses 15 (3), 698, 2023202
4
2023
COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity
K Lundstrom, A Hromić-Jahjefendić, E Bilajac, AAA Aljabali, K Baralić, ...Cellular Signalling 101, 11095, 2023202
4
2023
Periodically aperiodic pattern of SARS-CoV-2 mutations underpins the uncertainty of its origin and evolution
SS Hassan, P Basu, EM Redwan, K Lundstrom, PP Choudhury, ...Environmental Research 20, 112092, 2022202
4
2022
Viral agents as potential drivers of diffuse large B-Cell lymphoma tumorigenesis
E Bilajac, L Mahmutović, K Lundstrom, U Glamočlija, J Šutković, A Sezer, ...Viruses 14 (10), 2105, 2022202
3
2022
Gene Therapy Cargoes Based on Viral Vector Delivery
K LundstromCurrent Gene Therapy 2 (2), 111-14, 20220
3
2023
COVID-19 in 2021
K Lundstrom, AAA AljabaliViruses 1 (10), 2098, 2021202
3
2021